IBC raises NIS 490m. in bond issue

IBC Ltd., a member of the Fishman Investment Group, announced on Thursday it has raised NIS 490m. in an offering of bonds that were rated "AA-stable."

By MATTHEW KRIEGER
September 23, 2007 07:49

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Industrial Buildings Corporation Ltd., a member of the Fishman Investment Group, announced on Thursday it has raised NIS 490m. in an offering of bonds that were rated "AA-stable." IBC is Israel's largest real estate company, owning a diverse portfolio of approximately 1.7 million sq. m. of income-producing properties worldwide including class A office buildings, shopping and retail centers, industrial and logistical facilities, as well as large scale median income and luxury income residential developments.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS